Cited by 1,248Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenomics and Rare Diseases

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The IARC TP53 database: New online mutation analysis and recommendations to users

Open access

Olivier, Magali, Eeles, Ros, Hollstein, Monica, Khan, Mohammed A., Harris, Curtis C., Hainaut, Pierre·2002·Human Mutation

DOI 10.1002/humu.10081

Open this paper in CoChat — free account Open PDF

Abstract

Mutations in the tumor suppressor gene TP53 are frequent in most human cancers. Comparison of the mutation patterns in different cancers may reveal clues on the natural history of the disease. Over the past 10 years, several databases of TP53 mutations have been developed. The most extensive of these databases is maintained and developed at the International Agency for Research on Cancer. The database compiles all mutations (somatic and inherited), as well as polymorphisms, that have been reported in the published literature since 1989. The IARC TP53 mutation dataset is the largest dataset available on the variations of any human gene. The database is available at www.iarc.fr/P53/. In this paper, we describe recent developments of the database. These developments include restructuring of the database, which is now patient-centered, with more detailed annotations on the patient (carcinogen exposure, virus infection, genetic background). In addition, a new on-line application to retrieve somatic mutation data and analyze mutation patterns is now available. We also discuss limitations on the use of the database and provide recommendations to users.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/humu.10081

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53 and Human Cancer: The First Ten Thousand Mutations
Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M. L., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 899
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241
p53 gene mutation: software and database
Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 185
p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Vahteristo, P., Tamminen, A., Karvinen, P., Eerola, H., Eklund, C., Aaltonen, L. A., BLOMQVIST, C. P., Aittomäki, K., & Nevanlinna, H. A. (2001) · PubMed · Cited by 180
p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer
Hussain, S. P., & Harris, C. C. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00028-9 · Cited by 164
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90233-c · Cited by 153
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 3

Greenblatt, 1994, Cancer Res, 54, 4855
Hollstein, 1994, Nucleic Acids Res, 22, 3551
Vahteristo, 2001, Cancer Res, 61, 5718

Sorted by citations

Items 201–300 of 1,000

Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library
Shiraishi, K., Kato, S., Han, S., Liu, W., Otsuka, K., Sakayori, M., Ishida, T., Takeda, M., Kanamaru, R., Ohuchi, N., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310815200 · Cited by 95
p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma
Roh, J., Kang, S. K., Minn, I., Califano, J. A., Sidransky, D., & Koch, W. M. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.10.011 · Cited by 92
Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing
Rana, H. Q., Gelman, R. S., LaDuca, H., McFarland, R. E., Dalton, E., Thompson, J. D., Speare, V., Dolinsky, J. S., Chao, E., & Garber, J. E. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy001 · Cited by 96
Regulatory role of resveratrol, a microRNA-controlling compound, in HNRNPA1 expression, which is associated with poor prognosis in breast cancer
Otsuka, K., Yamamoto, Y., & Ochiya, T. (2018) · Oncotarget · doi:10.18632/oncotarget.25339 · Cited by 96
DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer
Wu, D.-W., Lee, M.-C., Wang, J., Chen, C.-Y., Cheng, Y.-W., & Lee, H. (2013) · Oncogene · doi:10.1038/onc.2013.107 · Cited by 95
A global suppressor motif for p53 cancer mutants
Baroni, T. E., Wang, T., Hua, Q., Dearth, L. R., Truong, L. N., Zeng, J., Denes, A. E., Chen, S. W., & Brachmann, R. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401162101 · Cited by 93
Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export
Shinozaki, T., Nota, A., Taya, Y., & Okamoto, K. (2003) · Oncogene · doi:10.1038/sj.onc.1207176 · Cited by 93
Finding driver mutations in cancer: Elucidating the role of background mutational processes
Brown, A., Li, M., Goncearenco, A., & Panchenko, A. R. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006981 · Cited by 90
MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C
Dharel, N., Kato, N., Muroyama, R., Moriyama, M., Shao, R., Kawabe, T., & Omata, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0111 · Cited by 92
Population-Based Estimate of the Contribution of TP53 Mutations to Subgroups of Early-Onset Breast Cancer: Australian Breast Cancer Family Study
Mouchawar, J., Korch, C. T., Byers, T., Pitts, T. M., Li, E., McCredie, M. R. E., Giles, G. G., Hopper, J. L., & Southey, M. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-0851 · Cited by 92
Correlation of Levels of Folded Recombinant p53 in Escherichia coli with Thermodynamic Stability in Vitro
Mayer, S., Rüdiger, S., Ang, H. C., Joerger, A. C., & Fersht, A. R. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.06.044 · Cited by 92
Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma
Xu, Q., Leong, J., Chua, Q. Y., Chi, Y. T., Chow, P. K. H., Pack, D. W., & Wang, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.044 · Cited by 89
The Notch Regulator MAML1 Interacts with p53 and Functions as a Coactivator
Zhao, Y., Katzman, R. B., Delmolino, L. M., Bhat, I., Zhang, Y., Gurumurthy, C. B., Germaniuk-Kurowska, A., Reddi, H. V., Solomon, A., Zeng, M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608974200 · Cited by 91
Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1
Gutmann, D. H., James, C. D., Pöyhönen, M., Louis, D. N., Ferner, R. E., Guha, A., Hariharan, S., Viskochil, D. H., & Perry, A. (2003) · Neurology · doi:10.1212/wnl.61.10.1397 · Cited by 89
Monocytic Leukemia Zinc Finger (MOZ) Interacts with p53 to Induce p21 Expression and Cell-cycle Arrest
Rokudai, S., Aikawa, Y., Tagata, Y., Tsuchida, N., Taya, Y., & Kitabayashi, I. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805101200 · Cited by 95
Lack of Correlation between p53-Dependent Transcriptional Activity and the Ability to Induce Apoptosis among 179 Mutant p53s
Kakudo, Y., Shibata, H., Otsuka, K., Kato, S., & Ishioka, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2935 · Cited by 88
The Histone Lysine Demethylase JMJD3/KDM6B Is Recruited to p53 Bound Promoters and Enhancer Elements in a p53 Dependent Manner
Williams, K., Christensen, J. F., Rappsilber, J., Nielsen, A. L., Johansen, J. V., & Helin, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096545 · Cited by 91
Metabolic Dependencies in Pancreatic Cancer
Gohar, A. V., Zarei, M., Brody, J. R., & Winter, J. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00617 · Cited by 87
Restoration of wild‐type p53 function in human cancer: Relevance for tumor therapy
Bossi, G., & Sacchi, A. (2007) · Head & Neck · doi:10.1002/hed.20529 · Cited by 86
Formation of Disulfide Bond in p53 Correlates with Inhibition of DNA Binding and Tetramerization
Sun, X. Z., Vinci, C., Makmura, L., Han, S., Tran, D., Nguyen, J., Hamann, M. J., Grazziani, S., Sheppard, S., Gutova, M., et al. (2003) · Antioxidants and Redox Signaling · doi:10.1089/152308603770310338 · Cited by 86
Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens
Wallerand, H. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh275 · Cited by 86
T Cell Deficiency Leads to Liver Carcinogenesis in Azoxymethane-Treated Rats
Wu, B., Ootani, A., Iwakiri, R., Sakata, Y., Fujise, T., Amemori, S., Yokoyama, F., Tsunada, S., Toda, S., & Fujimoto, K. (2006) · Experimental Biology and Medicine · doi:10.1177/153537020623100111 · Cited by 85
Tumor suppression by p53: making cells senescent.
Qian, Y., & Chen, X. (2010) · PubMed · doi:10.14670/hh-25.515 · Cited by 85
Pathway‐level mutational signatures predict breast cancer outcomes and reveal therapeutic targets
Posta, M., & Győrffy, B. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70215 · Cited by 109
p53 as a target for anti-cancer drug development
Bouchet, B. P., de Fromentel, C. C., Puisieux, A., & Galmarini, C. M. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.10.005 · Cited by 90
Suppression of Glucosylceramide Synthase Restores p53-Dependent Apoptosis in Mutant p53 Cancer Cells
Liu, Y., Patwardhan, G. A., Bhinge, K. N., Gupta, V. K., Gu, X., & Jazwinski, S. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3107 · Cited by 86
Mutation Screening of the TP53 Gene by Temporal Temperature Gel Electrophoresis (TTGE)
Sørlie, T., Johnsen, H., Vu, P., Lind, G. E., Lothe, R. A., & Børresen‐Dale, A. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-739-6_25 · Cited by 84
Identification of the Spiro(oxindole-3,3′-thiazolidine)-Based Derivatives as Potential p53 Activity Modulators
Gomez-Monterrey, I. M., Bertamino, A., Porta, A., Carotenuto, A., Musella, S., Aquino, C., Granata, I., Sala, M., Brancaccio, D., Picone, D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100838z · Cited by 83
Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation
Tomso, D. J., Inga, A., Menéndez, D., Pittman, G. S., Campbell, M. R., Storici, F., Bell, D. A., & Resnick, M. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501721102 · Cited by 83
TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy‐associated tumours
Nedelko, T., Arlt, V. M., Phillips, D. H., & Hollstein, M. C. (2008) · International Journal of Cancer · doi:10.1002/ijc.24006 · Cited by 82
Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells
Fraser, M. E., Chan, S., Chan, S. S. L., Fiscus, R. R., & Tsang, B. K. (2005) · Oncogene · doi:10.1038/sj.onc.1209251 · Cited by 82
Unfolding, Aggregation, and Amyloid Formation by the Tetramerization Domain from Mutant p53 Associated with Lung Cancer
Higashimoto, Y., Asanomi, Y., Takakusagi, S., Lewis, M. S., Uosaki, K., Durell, S. R., Anderson, C. W., Appella, E., & Sakaguchi, K. (2006) · Biochemistry · doi:10.1021/bi051192j · Cited by 86
Cross‐talks between cyclooxygenase‐2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis
de Moraes, E., Dar, N. A., Gallo, C. V. D. M., & Hainaut, P. L. (2007) · International Journal of Cancer · doi:10.1002/ijc.22899 · Cited by 82
p53 mutations in human cholangiocarcinoma: a review
Khan, S. A., Thomas, H. C., Toledano, M. B., Cox, I. J., & Taylor-Robinson, S. D. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01106.x · Cited by 82
Therapeutic targeting of p53 by small molecules
Selivanova, G. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.02.006 · Cited by 84
Impact of race/ethnicity on molecular pathways in human cancer
Wiencke, J. K. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1257 · Cited by 81
The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes
Menendez, D., Inga, A., & Resnick, M. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2297-2308.2006 · Cited by 81
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)
Degtjarik, O., Golovenko, D., Diskin-Posner, Y., Abrahmsén, L., Rozenberg, H., & Shakked, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-27142-6 · Cited by 78
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79
p53 family proteins in thyroid cancer
Malaguarnera, R., Vella, V., Vigneri, R., & Frasca, F. (2007) · Endocrine Related Cancer · doi:10.1677/erc.1.01223 · Cited by 80
Do MDM2 SNP309 and TP53 R72P Interact in Breast Cancer Susceptibility? A Large Pooled Series from the Breast Cancer Association Consortium
Schmidt, M. K., Reincke, S., Broeks, A., Braaf, L. M., Hogervorst, F. B. L., Tollenaar, R. A. �. �., Johnson, N., Fletcher, O., Peto, J., Tommiska, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0738 · Cited by 79
Recognition of DNA by p53 Core Domain and Location of Intermolecular Contacts of Cooperative Binding
Rippin, T. M., Freund, S. M. V., Veprintsev, D. B., & Fersht, A. R. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00326-1 · Cited by 80
Detecting lung cancer in plasma with the use of multiple genetic markers
Andriani, F., Conte, D., Mastrangelo, T., Leon, M., Ratcliffe, C., Roz, L., Pelosi, G., Goldstraw, P. G., Sozzi, G., & Pastorino, U. (2003) · International Journal of Cancer · doi:10.1002/ijc.11510 · Cited by 80
Rapid repair of UVA‐induced oxidized purines and persistence of UVB‐induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells
Nia, A. B., Kim, S.-I., & Pfeifer, G. P. (2008) · The FASEB Journal · doi:10.1096/fj.07-105437 · Cited by 78
Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis
Iida, K., Itoh, K., Maher, J. M., Kumagai, Y., Oyasu, R., Mori, Y., Shimazui, T., Akaza, H., & Yamamoto, M. P. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm146 · Cited by 79
Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
Inao, T., Iida, Y., Moritani, T., Okimoto, T., Tanino, R., Kotani, H., & Harada, M. (2018) · Oncotarget · doi:10.18632/oncotarget.25370 · Cited by 79
p28, A first in class peptide inhibitor of cop1 binding to p53
Yamada, T., Christov, K. T., Shilkaitis, A. L., Bratescu, L., Green, A., Santini, S., Bizzarri, A. R., Cannistraro, S., Gupta, T. K. D., & Beattie, C. W. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.266 · Cited by 78
TP53 and head and neck neoplasms
Blons, H., & Laurent‐Puig, P. (2003) · Human Mutation · doi:10.1002/humu.10171 · Cited by 77
Evidence for Selective Expression of the p53 Codon 72 Polymorphs: Implications in Cancer Development
Siddique, M. M., Chowbay, B., Fiszer‐Maliszewska, Ł., Aggarwal, A., Tan, A., Tan, P. B. O., Soo, K. C., & Sabapathy, K. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0153 · Cited by 77
Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase
Okamoto, K., Taya, Y., & Nakagama, H. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.07.021 · Cited by 76
Retention of the Arginine Allele in Codon 72 of the p53 Gene Correlates with Poor Apoptosis in Head and Neck Cancer
Schneider‐Stock, R., Mawrin, C., Motsch, C., Boltze, C., Peters, B., Hartig, R., Buhtz, P., Giers, A., Rohrbeck, A., Freigang, B., et al. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63211-7 · Cited by 76
Transcription Domain-Associated Repair in Human Cells
Nouspikel, T., Hyka‐Nouspikel, N., & Hanawalt, P. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01263-06 · Cited by 76
Functional protein microarrays for parallel characterisation of p53 mutants
Boutell, J. M., Hart, D. J., Godber, B. L. J., Kozlowski, R. Z., & Blackburn, J. M. (2004) · PROTEOMICS · doi:10.1002/pmic.200300722 · Cited by 73
MicroRNA Expression and Clinical Outcome of Small Cell Lung Cancer
Lee, J., Voortman, J., Dingemans, A. C., Voeller, D. M., Pham, T. C., Wang, Y., & Giaccone, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021300 · Cited by 73
KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction
Okamoto, K., Kitabayashi, I., & Taya, Y. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.022 · Cited by 74
Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides
Tal, P., Eizenberger, S., Cohen, E., Goldfinger, N., Pietrokovski, S., Oren, M., & Rotter, V. (2016) · Oncotarget · doi:10.18632/oncotarget.7857 · Cited by 73
Detection of the p53 response in zebrafish embryos using new monoclonal antibodies
Lee, K.-C., Goh, W. L., Xu, M., Kua, N., Lunny, D. P., Wong, J. S., Coomber, D., Vojtĕsek, B., Lane, E. B., & Lane, D. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210695 · Cited by 73
Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
Arya, A. K., El-Fert, A., Devling, T., Eccles, R. M., Aslam, M. A., Rubbi, C. P., Vlatković, N., Fenwick, J. D., Lloyd, B. H., Sibson, D. R., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605739 · Cited by 74
Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions
Eldar, A., Rozenberg, H., Diskin‐Posner, Y., Rohs, R., & Shakked, Z. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt630 · Cited by 77
Multiplex padlock targeted sequencing reveals human hypermutable CpG variationsPreprint
Li, J. B., Gao, Y., Aach, J., Zhang, K., Kryukov, G. V., Xie, B., Ahlford, A., Yoon, J.-K., Rosenbaum, A. M., Zaranek, A. W., et al. (2009) · Genome Research · doi:10.1101/gr.092213.109 · Cited by 75
Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters
Lim, S. B., Lim, C. T., & Lim, W. (2019) · Cancers · doi:10.3390/cancers11101595 · Cited by 73
TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
Molica, M., Mazzone, C., Niscola, P., & de Fabritiis, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.610820 · Cited by 75
Distinct p53, p53:LANA, and LANA Complexes in Kaposi's Sarcoma-Associated Herpesvirus Lymphomas
Chen, W., Hilton, I. B., Staudt, M. R., Burd, C. E., & Dittmer, D. P. (2010) · Journal of Virology · doi:10.1128/jvi.01321-09 · Cited by 73
The human Tp53 Arg72Pro polymorphism explains different functional prognosis in stroke
Sánchez, J. C. G., Delgado‐Esteban, M., Rodríguez‐Hernández, I., Sobrino, T., de la Ossa, N. P., Reverté‐Villarroya, S., Bolaños, J. P., González‐Sarmiento, R., Castillo, J., & Almeida, Á. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20101523 · Cited by 72
Discrimination of p53 immunohistochemistry‐positive tumors by its staining pattern in gastric cancer
Ando, K., Oki, E., Saeki, H., Yan, Z., Tsuda, Y., Hidaka, G., Kasagi, Y., Otsu, H., Kawano, H., Kitao, H., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.346 · Cited by 71
TTK/hMps1 Mediates the p53-Dependent Postmitotic Checkpoint by Phosphorylating p53 at Thr18
Huang, Y., Chang, M. D., & Shieh, S.-Y. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01837-08 · Cited by 78
p53 Mutations in Benzo(a)Pyrene-Exposed Human p53 Knock-in Murine Fibroblasts Correlate with p53 Mutations in Human Lung Tumors
Liu, Z., Muehlbauer, K., Schmeiser, H. H., Hergenhahn, M., Belharazem, D., & Hollstein, M. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3675 · Cited by 71
TP53 and mutations in human cancer.
Szymańska, K., & Hainaut, P. L. (2003) · Acta Biochimica Polonica · doi:10.18388/abp.2003_3731 · Cited by 71
Extensive Post-translational Modification of Active and Inactivated Forms of Endogenous p53
DeHart, C. J., Chahal, J. S., Flint, S. J., & Perlman, D. H. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.030254 · Cited by 70
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells
Ali, D., Jönsson‐Videsäter, K., Deneberg, S., Bengtzén, S., Nahi, H., Paul, C., & Lehmann, S. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01557.x · Cited by 70
Inhibition of p53 DNA Binding Function by the MDM2 Protein Acidic Domain
Cross, B. L., Chen, L., Cheng, Q., Li, B., Yuan, Z.-M., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228981 · Cited by 72
Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression
Yan, W., Zhang, Y., Jin, Z., Liu, S., Cho, S. J., & Chen, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.231639 · Cited by 71
S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis
Martínez-Leal, J. F., Ferrer, I., Blanco‐Aparicio, C., Hernández‐Losa, J., y Cajal, S. R., Carnero, A., & LLeonart, M. E. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn198 · Cited by 71
Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells
Ichwan, S. J. A., Yamada, S., Sumrejkanchanakij, P., Auerkari, E. I., Eto, K., & Ikeda, M.-A. (2005) · Oncogene · doi:10.1038/sj.onc.1209158 · Cited by 68
Molecular classification and molecular genetics of human lung cancers
Meyerson, M. M., Franklin, W. A., & Kelley, M. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.009 · Cited by 68
Prediction by Graph Theoretic Measures of Structural Effects in Proteins Arising from Non-Synonymous Single Nucleotide Polymorphisms
Cheng, T. M. K., Lu, Y.-E., Vendruscolo, M., Lió, P., & Blundell, T. L. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000135 · Cited by 69
Genetic Mapping of a Third Li-Fraumeni Syndrome Predisposition Locus to Human Chromosome 1q23
Bachinski, L. L., Olufemi, S.-E., Zhou, X., Wu, C., Yip, L., Shete, S. S., Lozano, G., Amos, C. I., Strong, L. C., & Krahe, R. (2005) · Cancer Research · doi:10.1158/0008-5472.427.65.2 · Cited by 69
Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination
Cheok, C. F., Dey, A., & Lane, D. P. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0161 · Cited by 69
Potassium diazoacetate-induced p53 mutations in vitro in relation to formation of O6-carboxymethyl- and O6-methyl-2'-deoxyguanosine DNA adducts: relevance for gastrointestinal cancer
Gottschalg, E., Scott, G. B., Burns, P. A., & Shuker, D. E. G. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl150 · Cited by 69
COLD-PCR–Enhanced High-Resolution Melting Enables Rapid and Selective Identification of Low-Level Unknown Mutations
Milbury, C. A., Li, J., & Makrigiorgos, G. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.131029 · Cited by 69
p53-Regulated Networks of Protein, mRNA, miRNA, and lncRNA Expression Revealed by Integrated Pulsed Stable Isotope Labeling With Amino Acids in Cell Culture (pSILAC) and Next Generation Sequencing (NGS) Analyses
Hünten, S., Kaller, M., Drepper, F., Oeljeklaus, S., Bonfert, T., Erhard, F., Dueck, A., Eichner, N., Friedel, C. C., Meister, G., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.050237 · Cited by 70
Anomalous Dense Liquid Condensates Host the Nucleation of Tumor Suppressor p53 Fibrils
Safari, M. S., Wang, Z., Tailor, K., Kolomeisky, A. B., Conrad, J. C., & Vekilov, P. G. (2019) · iScience · doi:10.1016/j.isci.2019.01.027 · Cited by 70
Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer
Caponio, V. C. A., Troiano, G., Adipietro, I., Zhurakivska, K., Arena, C., Mangieri, D., Mascitti, M., Cirillo, N., & Muzio, L. L. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0984-6 · Cited by 68
Molecular Dynamics Simulations of p53 DNA-Binding Domain
Lü, Q., Tan, Y.-H., & Luo, R. (2007) · The Journal of Physical Chemistry B · doi:10.1021/jp0742261 · Cited by 68
DBC1 Functions as a Tumor Suppressor by Regulating p53 Stability
Qin, B., Minter‐Dykhouse, K., Yu, J., Zhang, J., Liu, T., Zhang, H., Lee, S., Kim, J.-J., Wang, L., & Lou, Z. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.066 · Cited by 65
PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68
Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells
Zhao, J., Lü, Y., & Shen, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.040 · Cited by 72
Mutant p53 interactome identifies nardilysin as a p53R273H‐specific binding partner that promotes invasion
Coffill, C. R., Muller, P. A. J., Oh, H. K., Neo, S. P., Hogue, K. A., Cheok, C. F., Vousden, K. H., Lane, D. P., Blackstock, W. P., & Gunaratne, J. (2012) · EMBO Reports · doi:10.1038/embor.2012.74 · Cited by 68
Molecular Features of Adult Glioma Associated with Patient Race/Ethnicity, Age, and a Polymorphism inO6-Methylguanine-DNA-Methyltransferase
Wiencke, J. K., Aldape, K., McMillan, A., Wiemels, J. L., Moghadassi, M., Miike, R., Kelsey, K. T., Patoka, J., Long, J. A., & Wrensch, M. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0089 · Cited by 68
Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma
Tam, K. H., Yang, Z. F., Lau, C. K., Lam, C. T., Pang, R. W. C., & Poon, R. T. P. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.08.018 · Cited by 67
A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma
Davies, A. J., Lee, A. M., Taylor, C., Clear, A. J., Goff, L. K., Iqbal, S., Heavens, D., Calaminici, M., Norton, A. J., Lister, T. A., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403802 · Cited by 68
Drug discovery and mutant p53
Maslon, M. M., & Hupp, T. R. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.06.005 · Cited by 68
p53–RNA interactions: New clues in an old mystery
Riley, K. J.-L., & Maher, L. J. (2007) · RNA · doi:10.1261/rna.673407 · Cited by 68
Specific TP53 mutation pattern in radiation-induced sarcomas
Britzen‐Laurent, N., Gibaud, A., Huygue, M., Lefèvre, S.-H., Bras, M. L., Chauveinc, L., Sastre‐Garau, X., Doz, F., Rouïc, L. L.-L., Chevillard, S., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi356 · Cited by 66
Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage
Logan, I. R., McNeill, H. V., Cook, S., Lü, X., Meek, D. W., Fuller-Pace, F. V., Lunec, J., & Robson, C. N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp180 · Cited by 68
Investigating the Intrinsic Aggregation Potential of Evolutionarily Conserved Segments in p53
Ghosh, S., Ghosh, D., Ranganathan, S., Arunagiri, A., Palanirajan, S. K., Jha, N. N., Padinhateeri, R., & Maji, S. K. (2014) · Biochemistry · doi:10.1021/bi500825d · Cited by 69
Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells
Ehrhardt, H., Häcker, S., Wittmann, S., Maurer, M., Borkhardt, A., Toloczko, A. D., Debatin, K., Fulda, S., & Jeremias, I. (2007) · Oncogene · doi:10.1038/sj.onc.1210666 · Cited by 65
Are there any more ovarian tumor suppressor genes? A new perspective using ultra high‐resolution copy number and loss of heterozygosity analysis
Gorringe, K. L., Ramakrishna, M., Williams, L. H., Sridhar, A., Boyle, S. E., Bearfoot, J. L., Li, J., Anglesio, M. S., & Campbell, I. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20694 · Cited by 65
Comparison of p53 Mutations Induced by PAH o-Quinones with Those Caused by anti-Benzo[a]pyrene Diol Epoxide in Vitro: Role of Reactive Oxygen and Biological Selection
Shen, Y.-M., Troxel, A. B., Vedantam, S., Penning, T. M., & Field, J. M. (2006) · Chemical Research in Toxicology · doi:10.1021/tx0601206 · Cited by 65
In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma
Knoops, L., Haas, R. L., Kemp, S. R. M., Majoor, D. M., Broeks, A., Eldering, E., de Boer, J. P., Verheij, M., van Ostrom, C., de Vries, A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-067579 · Cited by 65

Authors: Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P.
Affiliations: World Health Organization (CH)
German Cancer Research Center (DE)
National Institutes of Health (US)
Corresponding author: Hainaut, Pierre
ORCID: Olivier, Magali
Harris, Curtis C.
Hainaut, Pierre
Venue: Human Mutation
Publisher: Wiley
Published: 2002-05-03
Volume: 19
Issue: 6
Pages: 607-614
ISSN: 1059-7794 (ISSN-L)
1098-1004
DOI: 10.1002/humu.10081
OpenAlex: W2073576377
Cited by: 1,248
References: 14
Citations by year: 2026: 11 · 2025: 20 · 2024: 33 · 2023: 46 · 2022: 33 · 2021: 33 · 2020: 32 · 2019: 31 · 2018: 40 · 2017: 30 · 2016: 37 · 2015: 34 · 2014: 48 · 2013: 43 · 2012: 61
FWCI: 29.66
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4869 d)
Locations: Human Mutation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords: TP53 mutation, somatic mutations, TP53 polymorphisms, mutation patterns, cancer genomics, carcinogen exposure, viral infection, genetic background, database restructuring
MeSH terms: DNA Mutational Analysis, Humans, Mutation, Genes, Tumor Suppressor, Genes, p53, Li-Fraumeni Syndrome, Computational Biology, Internet, Databases, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The IARC TP53 database: New online mutation analysis and recommendations to users

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks